Nah, .07 would be the lowest if RMAT wasn't approved. We hit .06 based on settling the lawsuit with Northstar, and adding a new director. A lot has happened since then for the positive such as eliminating toxic debt, gaining a business partner to open 10 clinics nationwide, shifting the financial burden of marketing expenses, and a growing reality that we will likely see RMAT approval. RMAT was out there, but I really don't believe that RMAT was priced into the .08 share price yet. USRM was focused on staying in business at that time and Northstar could have realistically forced them into receivership.
The thing about this company is that they managed to have a revenue stream without Myocell in the US. I am guessing that they will show a profit of .02/share next q without RMAT approval based on the last Q as well as the role that GACP will play on the income statement. That would bring the stock price up substantially.
That all assumes the worst case scenario. Chances are really good that they get RMAT approval and we see a few bucks at worst and $18 at best. Then shortly after, we get a buyout offer.
News 
Market Data 
Discover 
